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the impact of specifi c genetic loci on BP have employed 24-hour 
BP measurements in large study samples. Indeed, our group is 
one of the few that has recently employed this approach to assess 
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NO SYNTHASE 
GENE AND 
AMBULATORY BP
INTRODUCTION                                                                    
A high proportion of the risk for cardiovascular events is attri-
buted to hypertension.(1) Despite the risk associated with hyper-
tension, apart from age and body size, the factors that account 
for most of the variation in blood pressure (BP) at a population 
level have remained elusive. Nevertheless, familial aggregation and 
heritability analyses indicate that a signifi cant proportion of BP 
variability can be attributed to genetic effects.(2-4) However, in this 
regard, there has been an inability to replicate genetic outcomes 
of even large studies evaluating genome-wide associations.(5,6)
The reasons for inconsistencies in the scientifi c literature with 
regards to the role of genetic loci in contributing to variations in 
BP are potentially numerous. However, one confounding factor 
that has been overlooked is that in the absence of repeated 
BP measurements obtained over considerable time periods,(6) 
24-hour ambulatory as opposed to offi ce BP measurements may 
be required to increase the ability to show familial aggregation 
or the heritability of BP.(2-4) Nevertheless few studies assessing 
Although nitric oxide (NO) plays an important role in 
blood pressure (BP) control, whether variation of genes 
involved in regulating the synthesis of NO infl uences BP 
is uncertain. As the heritability of BP is stronger for 
ambulatory than it is for conventional BP, we assessed the 
independent association of the well described functional 
exon 7 Glu298Asp variant of the eNOS gene with the 
presence of hypertension in 511 randomly selected normo-
tensive control participants and 503 hypertensives with a 
diagnosis of hypertension confi rmed with 24-hour ambu-
latory BP profi les whilst off therapy. We also assessed the 
relationship between eNOS genotype and 24 hour ambu-
latory BP. Comparisons of genotype and allele frequencies 
indicated a lack of association of the exon 7 Glu298Asp 
gene variant with hypertension (Odds ratio of genotype 
predicting the presence of hypertension=0.97, confi dence 
interval=0.70-1.30, p=0.92). However, patients with the 
Glu/Glu genotype of the Glu298Asp variant (n=424) had 
increased 24-hour systolic and diastolic blood pressures 
(152±1/97±1 mm Hg) in comparison to patients hetero-
zygous for the Glu298Asp variant or homozygous for the 
298Asp allele (n=79) (145±1/94±1 mm Hg, p<0.005 for sys-
tolic BP and p<0.001 for diastolic BP after multiple 
adjustments including age, gender, body mass index and 
the presence of diabetes mellitus). Differences in systolic 
and diastolic BP between genotype groups were noted 
during the day as well as at night. The association of eNOS 
genotype with ambulatory BP translated into an increased 
risk of more severe grades of hypertension in patients with 
the Glu/Glu genotype (grade II and III vs. grade I, Odds 
ratio=2.20, confi dence interval=1.34-3.59, p<0.0002). In 
conclusion, a functional gene variant (Glu298Asp) at the 
eNOS locus contributes ~1.4-2.5% to the variation in 
ambulatory blood pressure within hypertensives, but is not 
associated with the presence of hypertension in patients in 
whom the diagnosis has been confi rmed by 24-hour 
ambulatory BP values. The relationship between eNOS 
genotype and 24-hour ambulatory BP and the severity of 
hypertension warrants further study.  SAHeart 2009; 6:148-153
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the role of genes that infl uence the renin-angiotensin-aldosterone 
system in hypertension.(7,8) In addition, a study to determine the 
impact of leptin gene variants on blood pressure used ambulatory 
monitoring to assess blood pressure.(9) To extend these studies, 
in the present study we assessed the ability to detect a relation-
ship between a common variant of the endothelial nitric oxide 
synthase (eNOS) gene and the presence of hypertension con-
fi rmed with 24-hour BP measurements in a large case-control 
study. In this regard, in studies employing conventional BP 
measurements to identify the presence of hypertension or the 
variability of BP, the role of the eNOS gene in contributing 
to hypertension or BP variability has produced inconsistent 
outcomes.(10-21)
METHODS                                                                                       
Study groups
Five hundred and three consecutive hypertensive patients of 
African ancestry initially screened at district clinics in suburban 
areas of Johannesburg and referred to tertiary care centres 
(Johannesburg and Chris Hani-Baragwanath Hospital) for more 
thorough clinical assessments were recruited if they had mean 
daytime ambulatory diastolic BPs (DBPs) >90 mm Hg (Space-
Labs model 90207) off medication. Ambulatory BP measure-
ments were performed on patients with auscultatory BPs <200/
115 mm Hg after at least 2 weeks off medication. A minority of 
patients (6%) with either fi rst auscultatory BPs ≥200/115 mm Hg; 
or with either target organ damage; or two or more additional 
risk factors for cardiovascular disease had 24-hour BP monitoring 
performed within a shorter period off medication (4 days). To 
reduce the possibility of population stratifi cation only patients of 
the Nguni, Sotho and Venda chiefdoms of South Africa were 
selected. In addition, patients with type I diabetes mellitus, 
uncontrolled type II diabetes mellitus (defi ned as a HbA1c> 10%), 
renal and endocrine disease and clinically important cardiac 
pathology (clinically signifi cant arrhythmias, heart failure, valvular 
disease, ischaemic heart disease, previous myocardial infarction, 
and unstable angina) were excluded. Five hundred and eleven 
control participants of African descent without a family history of 
hypertension were recruited from suburban areas of Johannes-
burg and were considered to be normotensive if the mean of 
3 auscultatory and the mean of 3 oscillometric (SpaceLabs model 
90207) DBPs were <90 mm Hg after 5 minutes of rest in the 
seated position and if the subjects had been residents of an urban 
area for at least 2 years.
Ambulatory blood pressures and grading of hypertension
Ambulatory BP measurements were performed at least every 
half hour during the day (06:00 to 22:00 hours) and hourly 
during the night (22:00 to 06:00). Ambulatory monitors were 
calibrated using standard techniques. All patients were advised 
not to smoke, drink alcohol, or ingest caffeine during this period. 
Five hundred and three patients had >90% and the remaining 
>85% of intended ambulatory BP recordings obtained. The 
grading of hypertension was based on the mean values obtained 
for daytime ambulatory BP and the categories (I, II and II) were 
according to those described in guidelines for the diagnosis and 
management of hypertension.(1)
Genotyping
Deoxyribonucleic acid was extracted from whole blood by lysing 
red blood cells and digesting the remaining white cell pellet with 
proteinase K. A functional variant(22) in exon 7 of the eNOS gene 
was studied, where a substitution of a thymidine for a guanine 
nucleotide at position 894 results in aspartate (Asp) replacing 
glutamate (Glu) in amino acid position 298 of the protein.(10-15,18-21) 
For the detection of the Glu298Asp variant, polymerase chain 
reaction-restriction fragment length polymorphism-based tech-
niques were employed. A 248 base pair fragment was amplifi ed 
from the primers 5’-AAG GCA GGA GAC AGT GGA TGG A-3’ 
(sense) and 5’-CCC AGT CAA TCC CTT TGG TGC TCA-3’ 
(antisense).(11) The restriction enzyme BanII produced 163 and 85 
base pair fragments in the presence of a guanine at nucleotide 
position 894 (Glu). The restriction enzyme NdeI produced 158 and 
90 base pair fragments in the presence of a thymidine at nucleo-
tide position 894.  
 
Data analysis
To test for Hardy Weinberg equilibrium, the expected genotype 
numbers were calculated from the allele frequencies and deviation 
from the observed genotype numbers was determined using a 
X2 test. Effects of genotypes on the presence of hypertension 
or the severity of hypertension (grade II and II versus grade I) was 
evaluated using logistic regression analysis with age, gender and 
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body mass index (BMI) and history of smoking or alcohol 
consumption included as covariates. The impact of genotype on 
ambulatory BP and pulse pressure was evaluated by ANCOVA 
with age, gender, body mass index, duration of hypertension, 
history of smoking or alcohol consumption, previous drug therapy, 
and the presence or absence of type II diabetes mellitus included 
as covariates.
RESULTS                                                                                      
Demographic and clinical characteristics
Demographic and clinical data for the study groups are shown in 
Table 1. Both the case and the control groups had more females 
than males and a mean body mass index that refl ects a high 
prevalence of obesity. The high proportion of females in both 
groups refl ects the gender distribution of patients attending 
district clinics rather than a greater incidence of hypertension in 
women as compared to men. Except for a higher BMI in the case 
group, the case and control groups were matched for all other 
demographic features. However, the eNOS Glu/Glu genotype 
group in the hypertensives consisted of more females (p<0.05) 
and had a trend for a higher mean BMI (p<0.05) than the patients 
with the Glu/Asp and Asp/Asp genotypes. 
Genotype effects on the risk of hypertension
The genotype frequencies of the eNOS gene variant in the case 
and the control groups are given in Table 2. The genotype fre-
quencies were in Hardy Weinberg equilibrium for both the case 
and the control groups. The eNOS gene variant was however 
not independently associated with the presence of hypertension 
(Table 2).
Genotype effects on ambulatory blood pressure
Figure 1 shows the 24-hour ambulatory systolic and diastolic 
blood pressures and Figure 2 shows the mean 24-hour, day and 
night ambulatory blood pressure profi les of hypertensive patients 
grouped according to eNOS gene Glu298Asp polymorphism 
genotypes. Patients with the Glu/Glu genotype had higher 24-
hour, day and night systolic and diastolic BP values as compared 
to patients with the other genotypes. Indeed patients with the 
Glu/Glu genotype had a 4.5% (~7 mm Hg) greater 24-hour 
systolic BP and a 3.5% (~3 mm Hg) greater 24-hour diastolic BP 
compared to patients with the other genotypes. The eNOS 
genotype contributed ~1.4-2.5% to the variation in ambulatory 
blood pressure within hypertensive patients. Pulse pressure did 
not differ according to eNOS gene Glu298Asp polymorphism 
genotypes (Glu/Glu: 54±1 mm Hg, Glu/Asp+Asp/Asp: 53±1 mm 
Hg, p=0.17).
Genotype effects on the severity of daytime ambulatory 
blood pressure
Table 2, lower panel shows the proportion of patients with grade II 
and III hypertension as compared to those with grade I hyper-
tension in the different eNOS genotype groups. Patients with the 
Glu/Glu genotype had a higher proportion of patients with grade II 
and III hypertension as compared to grade I hypertension.
NO SYNTHASE GENE AND AMBULATORY BP
TABLE 1:  Demographic and clinical characteristics of hypertensives and 
control participants
* p<0.05 versus the control group
 Control  Hypertensives
 (n=511)  (n=503)
Age (years) 52.1±0.4 51.3±0.6
Gender (Female/male, (% female)) 358/153 (70) 372/131 (74)
Body mass index (kg/m2) 29.2±0.30 30.6±0.30*
Duration of hypertension (years)   0 2.72±0.10*
Type II diabetes mellitus  2.7   5.0
Smoking (%)  20   18
Alcohol consumption (%)  18   17
TABLE 2: Comparison of genotype frequencies of the Glu298Asp variant 
of the endothelial nitric oxide gene between hypertensive and control 
participants of African ancestry and between different grades of hyperten-
sion (grade I versus grade II and III) within the hypertensive participants.
Odds ratio for Glu/Glu genotype associated with hypertension = 0.97, confi dence 
interval=0.70-1.30, Not signifi cant.
Odds ratio for Glu/Glu genotype associated with grade II and III hypertension as compared to 
grade I hypertension = 2.20, confi dence interval=1.34-3.59, p<0.0002.
 Glu/Glu Glu/Asp + 
  Asp/Asp
Hypertensives 424 (84.3%)     74+5 (15.7%)
Controls 429 (84.0%)     81+1 (16.0%)
Grade I Hypertension 145 (34.2%)      42 (53.2%)
Grade II+III Hypertension 279 (65.8%)      37 (46.8%)
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DISCUSSION                                                                           
The main fi ndings of the present study are that in a large study 
sample (n=1014), in which hypertension in the case group was 
confi rmed with ambulatory BP monitoring, the Glu298Asp 
polymorphism of the eNOS gene is not associated with the 
presence of hypertension. However, within the hypertensive 
group, patients with the Glu/Glu genotype had a ~3-7 mm Hg 
greater ambulatory BP than patients with other eNOS geno-
types, and the eNOS genotype was associated with the severity 
of hypertension and contributed ~1.4-2.5% to the variation in 
ambulatory blood pressure within hypertensive patients.
The present study is the fi rst to evaluate the relationship 
between the well described functional(21) Glu298Asp variant of 
the eNOS gene and the presence of hypertension in patients 
in whom the diagnosis was confi rmed with ambulatory BP 
monitoring whilst off medication. Previous studies have evaluated 
the relationships between eNOS gene variants and the presence 
FIGURE 1: 24-Hour ambulatory systolic (SBP) and diastolic 
(DBP) blood pressure profi les of hypertensive patients grouped 
according to eNOS gene Glu298Asp polymorphism genotypes. 
Glu/Glu, patients homozygous for the Glu298 variant; Asp/Asp, 
patients homozygous for the 298Asp variant; Glu/Asp, patients 
heterozygous for the Glu298Asp variant. Comparisons of blood 
pressures are made in Figure 2.
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FIGURE 2: Mean 24-hour, day and night ambulatory systolic 
(SBP) and diastolic (DBP) blood pressure profi les of hypertensive 
patients grouped according to eNOS gene Glu298Asp polymor-
phism genotypes. Glu/Glu, patients homozygous for the Glu298 
variant; Asp/Asp, patients homozygous for the 298Asp variant; 
Glu/Asp, patients heterozygous for the Glu298Asp variant. Pro-
bability values indicate comparisons between genotype groups.
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of hypertension diagnosed according to guidelines, but without 
a confi rmation of elevated BP values from 24-hour measure-
ments.(10-21) In this regard there is considerable uncertainty as to 
the role of the Glu298Asp variant in determining the presence 
of hypertension or the variability of offi ce BP, with some studies 
demonstrating a relationship between the Asp/Asp and Glu/Asp 
genotypes and the presence of hypertension,(12,13,15) another a 
relationship between the Glu/Glu genotype and hypertension,(10) 
whilst in further studies a lack of relationship between the 
Glu298Asp genotype and the presence of hypertension was 
noted.(18-21) In this regard, the strongest evidence, obtained in 
large study samples (n=1165-4055),(18,20) indicates that the 
Glu298Asp variant is indeed not associated with hypertension. 
Moreover, our study, also conducted in a large study sample 
(n=1014) and with the additional benefi t of the presence of 
diastolic hypertension confi rmed off medication using ambulatory 
BP monitoring, concurs with the outcomes of previous studies 
conducted in large study samples(18,20) indicating that the Glu298
Asp variant is indeed not associated with hypertension.
Although in the present study we were unable to show a relation-
ship between Glu298Asp genotype and the presence of hyper-
tension, we were able to show a fairly robust relationship between 
this genotype and ambulatory BP in hypertensives not receiving 
medication at the time of assessment. These data would suggest 
that the eNOS gene may be associated with BP, but that the 
sensitivity to detect an effect is enhanced by considering BP as a 
continuous rather than a dichotomous trait and employing 
ambulatory BP to assess these effects. This is indeed consistent 
with the notion that ambulatory BP measurements enhance the 
ability to detect a genetic effect as previously proposed.(2-4)
It may be argued that the genetic association described in the 
present study with ambulatory BP in hypertensives is of little clinical 
relevance if ambulatory BP is required to detect a difference in BP 
between genotype groups. Importantly, however, the differences 
in ambulatory BP detected in patients with the Glu/Glu as 
compared to those with the Glu/Asp and Asp/Asp genotypes 
were of clinical signifi cance in that they translated into an associa-
tion with different grades of severity of hypertension defi ned 
according to mean daytime BP measurements. In this regard, 
grade II and III hypertension carries a signifi cantly greater risk of 
a cardiovascular event than grade I hypertension.(1)
An explanation for the relationship between the Glu/Glu geno-
type of the Glu298Asp variant and an increased ambulatory BP 
was not explored in the present study. In this regard, the Asp298 
allele is associated with the production of an eNOS protein that 
is more susceptible to cleavage than the 298Glu allele(22) an effect 
that is likely to reduce NO production and consequently increase 
and not decrease BP as reported on by our group. Hence, in the 
present study two explanations for the relationships between 
genotype and ambulatory BP need to be considered. First, the 
Glu298Asp variant may be in linkage disequilibrium with an 
alternative functional eNOS gene variant. Second, the association 
noted may be explained by an increased mortality in hypertensive 
participants with the Asp298 allele with more severe forms of 
hypertension. In the latter case the remaining patients with the 
Asp298 allele would have lower BP values as reported on by us. 
Only prospective studies will be able to evaluate this hypothesis.
The strengths of the present study include the relatively large 
study sample evaluated (n=1014) and the use of ambulatory BP 
in 503 hypertensives to assess the outcomes. The limitations of 
the present study include the lack of prospective analysis. Thus 
the outcomes of the present study may represent an epipheno-
menon. Moreover, the relationship between genotype and ambu-
latory BP was assessed in hypertensives rather than in a cross-
section of the population. In this regard, further work is being 
conducted to assess the relationship between eNOS genotype 
and ambulatory BP in ~750-1000 participants derived from a 
cross-section of the population.
In conclusion, in the present study conducted in a large cohort 
(n=1014) in which hypertension in the cases was confi rmed using 
24-hour ambulatory BP monitoring, we show that the functional 
Glu298Asp gene variant of the eNOS gene is not associated with 
hypertension. However, within the hypertensive group, a robust 
relationship between eNOS genotype and variations in ambulatory 
BP was observed.  The latter important relationship observed in the 
hypertensives requires further investigation. 
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